MedPath

Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters

Completed
Conditions
Alzheimer Disease
Interventions
Other: Medical file data extraction
Registration Number
NCT03408041
Lead Sponsor
Murielle Surquin
Brief Summary

The early diagnosis of Alzheimer's disease is essential to enable patients to have access to the available treatments. However, there is a delay between the diagnosis and the onset of symptoms, which can range from 1 year to more than 5 years. In clinical practice, the hippocampal volume, measured by the Scheltens index, is currently used as a marker of the progression of the disease.

The purpose of this study is to determine whether the patient's sex, age and ethnicity can influence the delay in the expression of cognitive troubles reported by the family at the first medical consultation, as well as to determine if there is a correlation between the delay reported by the family and the Scheltens index.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
129
Inclusion Criteria

Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria

Exclusion Criteria

None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Alzheimer DiseaseMedical file data extractionAlzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
Primary Outcome Measures
NameTimeMethod
AgeBetween 01-01-2010 and 31-01-2013

Age

SexBetween 01-01-2010 and 31-01-2013

Sex

Ethnic originBetween 01-01-2010 and 31-01-2013

Ethnic origin

Symptoms-diagnose time intervalBetween 01-01-2010 and 31-01-2013

Interval of time between the apparition of the first symptoms, as reported by the family, and the diagnose.

Scheltens scaleBetween 01-01-2010 and 31-01-2013

Evaluation of the hippocampal atrophy by means of magnetic resonance imaging. Scale from 0 (normal) to 4.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Brugmann

🇧🇪

Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath